Thoracic Cancer (Jan 2024)

Diagnostic method of mass spectrometry for detecting lymph node metastasis of non‐small cell lung cancer

  • Ryuichi Yoshimura,
  • Wataru Shigeeda,
  • Yuji Fujita,
  • Tetsuo Kokaji,
  • Hiroyuki Deguchi,
  • Makoto Tomoyasu,
  • Satoshi Kudo,
  • Yuka Kaneko,
  • Hironaga Kanno,
  • Hidenobu Iwai,
  • Tomohiko Mase,
  • Hajime Saito

DOI
https://doi.org/10.1111/1759-7714.15179
Journal volume & issue
Vol. 15, no. 3
pp. 209 – 214

Abstract

Read online

Abstract Background Histopathology by pathologists is essential in the diagnosis of non‐small cell lung cancer (NSCLC). However, auxiliary diagnostic procedures for malignant tumor have continued to evolve. Despite the poor prognosis of patients with NSCLC, the application of the latest procedures and technologies to the field of lung cancer has lagged. Mass spectrometry was used to detect trace amounts of peptides in human tissue with high accuracy. The aim of this study was to establish a method for diagnostic mass spectrometry to identify lymph node metastasis by detecting cytokeratin (CK)19, a useful biomarker in lung cancer. Methods We collected 81 lymph nodes with positive expression of CK19 in patients who underwent radical surgical resection in the Department of Thoracic Surgery at Iwate Medical University between May 2020 and December 2022. An X500R instrument was used for sample analysis. A positive result for lymph node metastasis as the detection at least two product ions (FGPGVAFR and ILGATIENSR) from CK19 was defined. Results Our study indicated a high diagnostic efficiency for mass spectrometry, with 87.5% sensitivity and 91.2% specificity. The mutual concordance of mass spectrometry methods and histopathological diagnosis was 90.1%. Conclusions Mass spectrometry offers high diagnostic accuracy and can be clinically applied to auxiliary diagnostic procedures for lymph node metastasis from NSCLC.

Keywords